Market Cap (In USD)
73.2 Million
Revenue (In USD)
-
Net Income (In USD)
-123.56 Million
Avg. Volume
184.63 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.55-20.22
- PE
- -0.49
- EPS
- -3.0
- Beta Value
- 0.773
- ISIN
- US43157M1027
- CUSIP
- 43157M102
- CIK
- 1888012
- Shares
- 50141064.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Robert M. Hershberg M.D., Ph.D.
- Employee Count
- -
- Website
- https://www.hillevax.com
- Ipo Date
- 2022-04-29
- Details
- HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
More Stocks
-
NTDOYNintendo Co., Ltd.
NTDOY
-
SOLISolid State plc
SOLI
-
ORV
-
LNC-PDLincoln National Corporation
LNC-PD
-
GLINT
-
ZODIACLOTHZodiac Clothing Company Limited
ZODIACLOTH
-
SPXCF
-
TCEHYTencent Holdings Limited
TCEHY